Summary & Overview
CPT 81430: Genomic Sequence Analysis Panel for Hearing Loss and Related Genes
CPT code 81430 represents a genomic sequence analysis panel designed to evaluate a patient specimen for genetic sequences across at least 60 genes, including 16 genes associated with hearing loss. This code is significant nationally as it supports advanced molecular diagnostics, enabling clinicians to identify genetic factors that may contribute to hearing impairment and other conditions. The procedure is typically performed in laboratory settings and is part of the broader category of Genomic Sequencing Procedures and Other Molecular Multianalyte Assays.
Major payers covering this code include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication provides an overview of payer coverage, clinical context, and policy updates relevant to this code. Readers will gain insights into benchmarks for utilization, recent changes in payer policies, and the clinical applications of genomic sequencing panels. The summary also highlights the importance of this code in expanding access to precision medicine and supporting evidence-based care for patients with suspected genetic hearing loss and other related conditions.
Key topics include payer coverage trends, clinical indications, and the role of laboratories in delivering these advanced diagnostic services. The publication is intended for healthcare professionals, policy analysts, and laboratory administrators seeking up-to-date information on CPT code 81430 and its impact on clinical practice and reimbursement.
CPT Code Overview
CPT code 81430 is used for genomic sequence analysis panels that evaluate a patient specimen for genetic sequences of at least 60 genes. This includes 16 specific genes listed in the code descriptor, which may relate to hearing loss. The procedure falls under Genomic Sequencing Procedures and Other Molecular Multianalyte Assays, providing comprehensive genetic information that can inform clinical decision-making, particularly in cases involving hearing impairment. The typical site of service for this procedure is a laboratory (POS 81), where specialized equipment and expertise are required to perform the sequencing and analysis.
Clinical & Coding Specifications
Clinical Context
A patient, often a child or adult presenting with unexplained hearing loss, is referred for genomic sequence analysis to evaluate for potential genetic causes. The ordering provider, such as an audiologist or hearing instrument specialist, collects a specimen (typically blood or saliva) and sends it to a laboratory (Place of Service 81). The laboratory performs a genomic sequencing panel that analyzes at least 60 genes, including 16 specifically associated with hearing loss. The results help guide further clinical management, genetic counseling, and potential treatment options.
Coding Specifications
-
Modifier
26: Used when reporting only the professional component of the service, such as interpretation of the genomic sequencing results by a qualified provider. -
Modifier
TC: Used when reporting only the technical component, which includes specimen processing and laboratory analysis.
| Modifier Code | Description |
|---|---|
26 | Professional Component |
TC | Technical Component |
- Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
237600000X | Audiologist‑Hearing Aid Fitter |
237700000X | Hearing Instrument Specialist |
Related Diagnoses
-
Z13.79: Encounter for other screening for genetic and chromosomal anomalies- Used when the genomic sequencing is performed as a screening test for genetic causes of hearing loss.
-
Z15.89: Genetic susceptibility to other disease- Indicates the patient has a genetic predisposition to diseases, relevant when evaluating hereditary hearing loss.
-
Z51.81: Encounter for therapeutic drug level monitoring- May be relevant if genomic results influence medication management or monitoring.
-
F19.90: Other psychoactive substance use, unspecified, uncomplicated- Included for cases where substance use may impact hearing or genetic evaluation.
-
I25.10: Atherosclerotic heart disease of native coronary artery without angina pectoris- Used if the patient has comorbid heart disease, which may be relevant in syndromic genetic conditions affecting hearing.
Related CPT Codes
81431: Genomic sequencing procedures panel; hearing loss > 60 gene panel, duplications/deletions
81431 is related to 81430 as it also evaluates hearing loss using genomic sequencing, but specifically includes analysis for gene duplications and deletions in panels with more than 60 genes. In clinical workflow, 81431 may be used as an alternative or in conjunction with 81430 when a more comprehensive genetic analysis is required.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 81430 among BUCA (average commercial) payers is $1,257.05, which is substantially higher than the typical Medicare rate for similar codes. Commercial payers such as Blue Cross Blue Shield, UnitedHealth Group, Aetna, and Cigna all report mean rates above $1,180, with Blue Cross Blue Shield at the top at $1,347.20.
Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $1,391.50 between its 75th and 25th percentiles, indicating substantial variability in contracted rates. In contrast, Aetna has the tightest range at $520.00, suggesting more consistent reimbursement levels. Blue Cross Blue Shield and UnitedHealth Group fall in between, with ranges of $675.00 and $780.00, respectively.
The table and chart below present a detailed breakdown of national mean rates and percentile values for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.